The purpose of this FOA is to accelerate the implementation of activities to attain epidemic control of HIV in prioritized geographic areas by directly supporting service delivery and adopting data driven processes to increase ART coverage.
In the Caribbean, the HIV/AIDS epidemic is concentrated among KP, including MSM, SW and TG individuals. Within a TA framework, CDC CRO aims to support MOHs as they strive to reach the UNAIDS 90:90:90 targets. This FOA will expand the capacity of Caribbean MOHs to strategically address the HIV epidemics by supporting sustainable national efforts to improve and scale up high impact combination prevention along the HIV COPCT.
This project will support an evaluation of up to two locally-developed or adapted and potentially effective but insufficiently evaluated, interventions that are designed to deliver a combination of HIV prevention, HIV care and treatment, and other social and structural support services to transgender persons who have sex with men who are at risk for HIV infection or who are living with HIV.
The purpose of this funding opportunity is to evaluate the effects of an intervention that provides in-person assistance with health insurance or Medicaid enrollment following HIV testing on insurance uptake and coverage, linkage and retention rates (for HIV-positive men), and other health outcomes among Black men who have sex with men (MSM).
The purpose of this Funding Opportunity Announcement (FOA) is to support projects to identify and/or validate biomarkers or biomarker combinations leading to improved diagnosis of active pulmonary tuberculosis (TB) in children, including HIV infected children.
This Funding Opportunity Announcement (FOA) on the Human Immunology Project Consortium (HIPC) solicits applications from single institutions, or consortia of institutions, to participate in a network of human immunology profiling research groups in the area of infectious diseases, including HIV. The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, adjuvants or natural infection by capitalizing on recent advances in immune profiling technologies.
The goal of this Funding Opportunity Announcement (FOA) is to support innovative, basic and translational, nonexempt human subjects research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to GI pathology.
The goal of this Funding Opportunity Announcement (FOA) is to support innovative research in humans to elucidate the role of HIV infection, including relevant host conditions or antiretroviral therapy, on metabolic and endocrine dysfunction, as well as to support innovative research delineating the pathophysiology, etiology, risk or protective factors, and potential strategies to prevent, treat, or reverse endocrine and metabolic dysfunction in HIV-infected individuals. Proposed projects must involve human subjects with HIV infection or materials or data from HIV-infected individuals.
The objective of this Funding Opportunity Announcement (FOA) is to solicit hypothesis-driven, multidisciplinary research to elucidate the complexities and developmental plasticity of B cells associated with the induction of potent, durable, adaptive immune responses against HIV-1.
The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.